PLEASANTON, Calif.--(BUSINESS WIRE)--Veeva Systems (NYSE: VEEV) today announced that an increasing number of companies are adopting Veeva Vault CDMS to manage their clinical data. More emerging biotechs and global organizations, including a second top 20 pharmaceutical company, are modernizing clinical data management with Vault CDMS and starting studies faster. Vault CDMS has been used in over 100 trials, for studies in all phases and across diverse therapeutic areas.
Vault CDMS is a modern cloud application suite that combines EDC, coding, data cleaning, and reporting. Customers are building study databases in less than four weeks and making mid-study amendments with zero downtime to run the trials they want without technology limitations.
New innovative capabilities such as configuring rules for edit checks and updating reference ranges across all studies reduce manual processes and provide faster, more precise ways of building and managing trial data. Companies can now accelerate trial database builds, improve efficiency for study teams, and increase consistency in data management across CRO providers.
“Veeva Vault CDMS is helping organizations keep pace with the complexity of today’s clinical trial,” said Henry Levy, general manager, Vault CDMS, site, and patient solutions at Veeva. “Companies are standardizing on Veeva’s clinical data management suite for a fundamentally new approach to building studies and cleaning data.”
At the upcoming Veeva R&D & Quality Summit, Oct. 13-14, 2020, leading organizations will discuss how standardizing on Vault CDMS helps them build and clean studies faster and more efficiently, including:
- Eli Lilly and Company modernizing their data management infrastructure to aggregate all study data for centralized data cleaning and transformation.
- Alcon supporting rapid study start-ups that are crucial for the quick development cycles of medical device products.
- Parker Institute of Cancer Immunotherapy handling the demands of highly complex studies that legacy systems struggle to support.
Vault CDMS is part of Veeva Vault Clinical Suite, the industry’s first cloud platform that unifies clinical data management and clinical operations. More than 300 companies are using Veeva clinical applications, including 45 sponsors using Veeva Vault EDC.
Veeva R&D & Quality Summit is an online event open to life sciences industry professionals. Register and view the agenda at veeva.com/Summit.
For more on Veeva Vault CDMS, visit: veeva.com/VaultCDMS
Connect with Veeva on LinkedIn: linkedin.com/company/veeva-systems
Follow @veevasystems on Twitter: twitter.com/veevasystems
Like Veeva on Facebook: facebook.com/veevasystems
About Veeva Systems
Veeva Systems Inc. is a leader in cloud solutions—including data, software, and services—for the global life sciences industry. Committed to innovation, product excellence, and customer success, Veeva serves more than 900 customers, ranging from the world's largest pharmaceutical companies to emerging biotechs. The company is headquartered in the San Francisco Bay Area, with offices throughout North America, Europe, Asia, and Latin America. For more information, visit veeva.com.
This release contains forward-looking statements, including the market demand for and acceptance of Veeva’s products and services, the results from use of Veeva’s products and services, and general business conditions (including the on-going impact of COVID-19), particularly within the life sciences industry. Any forward-looking statements contained in this press release are based upon Veeva’s historical performance and its current plans, estimates, and expectations, and are not a representation that such plans, estimates, or expectations will be achieved. These forward-looking statements represent Veeva’s expectations as of the date of this press announcement. Subsequent events may cause these expectations to change, and Veeva disclaims any obligation to update the forward-looking statements in the future. These forward-looking statements are subject to known and unknown risks and uncertainties that may cause actual results to differ materially. Additional risks and uncertainties that could affect Veeva’s financial results are included under the captions, “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations,” in the company’s filing on Form 10-Q for the period ended July 31, 2020. This is available on the company’s website at veeva.com under the Investors section and on the SEC’s website at sec.gov. Further information on potential risks that could affect actual results will be included in other filings Veeva makes with the SEC from time to time.
® 2020 Veeva Systems Inc. All rights reserved. Veeva and the Veeva logo are trademarks of Veeva Systems Inc.
Veeva Systems Inc. owns other registered and unregistered trademarks.